VBI’s hepatitis B vaccine (recombinant) (PreHevbrio) is now available for the prevention of infection caused by all known subtypes of hepatitis B virus (HBV) in adults 18 years of age and older. It is the only approved three-antigen hepatitis B vaccine for adults in the United States. PreHevbrio was approved in November 2021 and added to the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices list of recommended adult HBV vaccines in February 2022.
Immunocompromised persons could have a diminished immune response to PreHevbrio. PreHevbrio might not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.
In clinical trials the most common side effects in adults were pain and tenderness at the injections site, myalgia, fatigue, and headache. A pregnancy exposure registry that monitors pregnancy outcomes in women who receive PreHevbrio during pregnancy has been established.
For full prescribing information, visit the manufacturer’s website.
